PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases
In Vivo · 2024-11 · 38 (6) · 2880-2885
DOI: 10.21873/invivo.13769 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2024. Verfasst von Pietro Pepe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Urology Unit, Cannizzaro Hospital, Catania, Italy; piepepe@hotmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Lymphatic Metastasis. Die Arbeit wurde bisher 30-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: This study aimed to evaluate the diagnostic accuracy of prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) in pelvic nodal staging, using postoperative histopathology data as the reference standard. PATIENTS AND METHODS: From January 2020 to June 2024, 78 patients with clinically significant prostate cancer (PCa) (ISUP Grade Group 2) underwent radical prostatectomy plus extended pelvic lymph node dissection (ePLND): 60 (77%) vs. 18 (23%) men had an intermediate vs. high risk PCa. All the patients underwent PSMA PET/TC before surgery for clinical staging and nodes focal uptake (standardized uptake value "SUVmax) was evaluated to rule out the presence of metastases. RESULTS: PSMA PET/CT was suspicious for nodes metastases in 16/78 (20.5%) men (median SUVmax 26.2), conversely, histology demonstrated nodes metastases in 18/78 (23.1%). PSMA PET/CT was negative for nodal involvement in all Grade Group 2 (GG2) PCa, positive in 4/4 (100%) GG3 PCa, and in 10/14 (71.4%) GG5 PCa. In detail, PSMA PET/CT was false negative in 2/4 PCa, characterized by GG5 plus ductal adenocarcinoma. Overall, PSMA PET/CT sensitivity, specificity, positive and negative predictive value, and diagnostic accuracy in diagnosing nodal metastases were equal to 87.5, 96.8, 87.5 96.7, and 92.3%, respectively. CONCLUSION: PSMA PET/CT demonstrated an overall diagnostic accuracy of 92.3% in nodal staging (100% in GG2 PCa), which decreased to 63.6% in GG5 PCa. In high-risk patients or in case of ductal adenocarcinoma, a negative PSMA PET/CT does not rule out the need for ePLND.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Unit, Cannizzaro Hospital, Catania, Italy; piepepe@hotmail.com.
- Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
- Pathology Unit, Cannizzaro Hospital, Catania, Italy.
- Urology Unit, Cannizzaro Hospital, Catania, Italy.
- Pathology Unit, ASP Catania, "Gravina" Hospital, Caltagirone, Italy.
Zitieren
APA
Pepe, P., Pepe, L., Fiorentino, V., Curduman, M., Pennisi, M., & Fraggetta, F. (2024). PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. In Vivo, 38(6), 2880-2885. https://doi.org/10.21873/invivo.13769
Vancouver
Pepe P, Pepe L, Fiorentino V, Curduman M, Pennisi M, Fraggetta F. PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. In Vivo. 2024;38(6):2880-2885. doi:10.21873/invivo.13769
BibTeX
@article{Pepe2024,
author = {Pepe, Pietro and Pepe, Ludovica and Fiorentino, Vincenzo and Curduman, Mara and Pennisi, Michele and Fraggetta, Filippo},
title = {PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases},
journal = {In Vivo},
year = {2024},
volume = {38},
number = {6},
pages = {2880--2885},
doi = {10.21873/invivo.13769}
}
EUVIMED